Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

ESMO 2021: PARPi data and their role in mono/combination therapies

Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong

ESMO 2021: PARPi data and their role in mono/combination therapies ( Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong )

ESMO 2021: Updates in hormone-sensitive prostate cancer

Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena...

ESMO 2021: Updates in hormone-sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Castro )

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant...

Dr Pascale Tomasini and Dr Catherine Shu

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC ( Dr Pascale Tomasini and Dr Catherine Shu )

ESMO 2021: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2021: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally...

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )

Drug combination shows promise in treatment-resistant advanced ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Drug combination shows promise in treatment-resistant advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal...

Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer ( Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA )

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin

Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after...

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron...

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed...

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

$Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )$

More from ecancer